CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Sartorius Stedim Biotech SA - DIM CFD

204.96
1.33%
Market Trading Hours* (UTC) Opens on Monday at 08:00

Mon - Fri: 08:00 - 16:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 1.08
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.022079 %
Charges from full value of position ($-4.20)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.022079%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.000143 %
Charges from full value of position ($-0.03)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.000143%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency EUR
Margin 5%
Stock exchange France
Commission on trade 0%

*Information provided by Capital.com

Sartorius Stedim Biotech SA ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 202.26
Open* 204.06
1-Year Change* -37.15%
Day's Range* 201.36 - 210.05
52 wk Range 160.55-358.80
Average Volume (10 days) 66.14K
Average Volume (3 months) 1.41M
Market Cap 18.67B
P/E Ratio 40.86
Shares Outstanding 92.17M
Revenue 2.96B
EPS 4.96
Dividend (Yield %) 0.71111
Beta 0.32
Next Earnings Date N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 8, 2023 204.96 3.30 1.64% 201.66 210.15 200.66
Dec 7, 2023 202.26 -0.90 -0.44% 203.16 203.96 199.86
Dec 6, 2023 204.96 7.84 3.98% 197.12 205.95 195.02
Dec 5, 2023 195.87 -3.30 -1.66% 199.17 199.47 193.92
Dec 4, 2023 199.76 -1.40 -0.70% 201.16 204.26 195.72
Dec 1, 2023 200.36 -4.40 -2.15% 204.76 206.05 198.82
Nov 30, 2023 207.45 0.50 0.24% 206.95 208.25 203.86
Nov 29, 2023 206.45 7.78 3.92% 198.67 206.85 198.62
Nov 28, 2023 199.96 1.29 0.65% 198.67 200.46 196.97
Nov 27, 2023 200.86 -0.90 -0.45% 201.76 204.96 199.76
Nov 24, 2023 203.16 0.90 0.44% 202.26 203.96 200.66
Nov 23, 2023 203.36 2.70 1.35% 200.66 203.86 200.16
Nov 22, 2023 201.86 2.70 1.36% 199.16 202.86 197.77
Nov 21, 2023 200.66 1.49 0.75% 199.17 201.36 197.72
Nov 20, 2023 199.47 0.55 0.28% 198.92 203.86 196.57
Nov 17, 2023 199.41 1.44 0.73% 197.97 204.96 197.97
Nov 16, 2023 197.72 -1.34 -0.67% 199.06 200.56 196.17
Nov 15, 2023 199.66 3.04 1.55% 196.62 203.76 195.57
Nov 14, 2023 196.87 15.08 8.30% 181.79 197.27 181.79
Nov 13, 2023 181.54 -3.70 -2.00% 185.24 186.94 180.45

Sartorius Stedim Biotech SA Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 3492.7 2886.98 1910.08 1440.57 1212.15
Revenue 3492.7 2886.98 1910.08 1440.57 1212.15
Cost of Revenue, Total 1658.2 1333.97 906.759 692.283 582.589
Gross Profit 1834.5 1553 1003.32 748.287 629.563
Total Operating Expense 2497.5 2021.56 1438.37 1108.73 911.918
Selling/General/Admin. Expenses, Total 602.6 531.596 394.576 319.561 283.778
Research & Development 132.4 110.491 84.451 79.216 60.616
Interest Expense (Income) - Net Operating 41.2 -8.891 -0.929 -0.008 0.011
Unusual Expense (Income) 46.3 26.451 32.66 16.813 -12.722
Other Operating Expenses, Total 16.8 27.935 20.85 0.863 -2.354
Operating Income 995.2 865.421 471.714 331.842 300.234
Interest Income (Expense), Net Non-Operating -11.8 -4.831 -4.922 2.79 -0.162
Other, Net 147 -213.87 -6.098 -17.213 -15.523
Net Income Before Taxes 1130.4 646.72 460.694 317.419 284.549
Net Income After Taxes 879.9 414.309 338.599 236.036 209.959
Minority Interest -3.8 0.104 -2.666 -1.535 -1.907
Net Income Before Extra. Items 876.1 414.413 335.933 234.501 208.052
Net Income 876.1 414.413 335.933 234.501 208.052
Income Available to Common Excl. Extra. Items 876.1 414.413 335.932 234.501 208.052
Income Available to Common Incl. Extra. Items 876.1 414.413 335.932 234.501 208.052
Dilution Adjustment
Diluted Net Income 876.1 414.413 335.932 234.501 208.052
Diluted Weighted Average Shares 92.1631 92.1768 92.1791 92.177 92.1768
Diluted EPS Excluding Extraordinary Items 9.50597 4.49585 3.64434 2.54403 2.2571
Dividends per Share - Common Stock Primary Issue 1.44 1.26 0.68 0.34 0.57
Diluted Normalized EPS 9.89702 4.67968 3.90475 2.81519 2.15526
Total Adjustments to Net Income -0.001
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total revenue 666.9 675.7 726.1 890 878.4
Revenue 666.9 675.7 726.1 890 878.4
Cost of Revenue, Total 386 350.8 351.6 416.9 417.4
Gross Profit 280.9 324.9 374.5 473.1 461
Total Operating Expense 590 562.8 572.4 667.8 624
Selling/General/Admin. Expenses, Total 149.7 143.2 152.8 152.3 154.6
Research & Development 28.4 28.8 35.4 38.5 28.9
Other Operating Expenses, Total 25.9 40 32.6 60.1 23.1
Operating Income 76.9 112.9 153.7 222.2 254.4
Interest Income (Expense), Net Non-Operating -41.4 46.1 -5.1 13.6 19.1
Other, Net -0.1 0.1 0
Net Income Before Taxes 35.5 158.9 148.6 235.9 273.5
Net Income After Taxes 26.3 133.1 111.5 189.7 205
Minority Interest -0.6 0 -0.4 -3 -0.6
Net Income Before Extra. Items 25.7 133.1 111.1 186.7 204.4
Net Income 25.7 133.1 111.1 186.7 204.4
Total Adjustments to Net Income 0 0.1
Income Available to Common Excl. Extra. Items 25.7 133.1 111.1 186.7 204.5
Income Available to Common Incl. Extra. Items 25.7 133.1 111.1 186.7 204.5
Diluted Net Income 25.7 133.1 111.1 186.7 204.5
Diluted Weighted Average Shares 91.7857 92.4306 91.8182 92.1551 92.1171
Diluted EPS Excluding Extraordinary Items 0.28 1.44 1.21 2.02593 2.22
Dividends per Share - Common Stock Primary Issue 0 0 0 1.44 0
Diluted Normalized EPS 0.48905 1.73181 1.35546 2.02593 2.28835
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 1671.2 1455.63 873.945 636.229 552.529
Cash and Short Term Investments 133 237.347 70.618 46.934 43.187
Cash & Equivalents 107.1 223.626 59.762 28.166 23.975
Short Term Investments 25.9 13.721 10.856 18.768 19.212
Total Receivables, Net 418.6 370.745 262.949 232.216 233.181
Accounts Receivable - Trade, Net 404.6 356.005 256.894 221.25 220.231
Total Inventory 1024.8 782.954 471.034 329.019 252.002
Other Current Assets, Total 94.8 64.583 69.344 28.06 24.159
Total Assets 5065.4 3951.1 2856.73 1845.36 1571.46
Property/Plant/Equipment, Total - Net 1292 928.413 644.272 549.965 435.98
Property/Plant/Equipment, Total - Gross 1732.9 1296.33 943.45 803.354 646.523
Accumulated Depreciation, Total -440.9 -367.92 -299.178 -253.387 -210.542
Goodwill, Net 1136.4 820.702 725.148 418.327 384.695
Intangibles, Net 876.8 684.417 571.882 208.487 177.492
Long Term Investments 24.9 14.769 13.497 14.427 5.644
Other Long Term Assets, Total 64.1 47.168 27.989 17.927 15.121
Total Current Liabilities 1035.9 1037.12 567.84 428.363 381.975
Accounts Payable 251.5 251.361 174.733 117.096 103.568
Accrued Expenses 74.1 97.159 59.899 40.634 39.335
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 24 40.444 23.987 54.531 91.534
Other Current Liabilities, Total 686.3 648.155 309.221 216.102 147.538
Total Liabilities 2616.1 2295.23 1418.61 686.643 535.063
Total Long Term Debt 1111.7 585.072 563.12 84.069 58.101
Long Term Debt 1020.6 521.072 515.657 40 43.125
Capital Lease Obligations 91.1 64 47.463 44.069 14.976
Deferred Income Tax 178.3 125.83 85.076 45.065 39.15
Minority Interest 64.9 77.361 22.876 30.164 8.476
Other Liabilities, Total 225.3 469.85 179.697 98.982 47.361
Total Equity 2449.3 1655.87 1438.12 1158.72 1036.4
Common Stock 18.4 18.436 18.436 18.436 18.436
Retained Earnings (Accumulated Deficit) 2410.5 1617.15 1440.8 1130.92 1009.97
Other Equity, Total 20.4 20.283 -21.111 9.361 7.988
Total Liabilities & Shareholders’ Equity 5065.4 3951.1 2856.73 1845.36 1571.46
Total Common Shares Outstanding 92.1673 92.1802 92.1802 92.1802 92.1802
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 1525 1618 1646.2 1671.2 1780.9
Cash and Short Term Investments 118.7 133.5 113 138.5 161.7
Cash & Equivalents 99.3 110 94 107.1 145.5
Short Term Investments 19.4 23.5 19 31.4 16.2
Total Receivables, Net 333.9 349.6 387.9 418.6 467.7
Accounts Receivable - Trade, Net 305.8 323.8 362 404.6 446.5
Total Inventory 992 1033.1 1060.9 1024.8 1058.6
Other Current Assets, Total 80.4 101.8 84.4 89.3 92.9
Total Assets 7958.9 5187.2 5096.7 5065.4 5097.1
Property/Plant/Equipment, Total - Net 1564.2 1455.2 1355.3 1292 1193.4
Goodwill, Net 2319.9 1150 1135.3 1136.4 1125.2
Intangibles, Net 2453.9 879.4 870.6 876.8 917.3
Long Term Investments 38.1 24.4 24.6 24.9 15.4
Other Long Term Assets, Total 57.8 60.2 64.7 64.1 64.9
Total Current Liabilities 853.6 922 1151.5 1035.9 1192.3
Accounts Payable 412.1 440.4 454.9 485.6 520.3
Accrued Expenses 90.9 81.1 91.3 74.1 104.6
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 34.1 27 194.6 24 73.7
Other Current Liabilities, Total 316.5 373.5 410.7 452.2 493.7
Total Liabilities 5364.3 2618 2676.4 2616.1 2824.3
Total Long Term Debt 3759.9 1331.6 1112.2 1111.7 1091.9
Long Term Debt 3662 1241.6 1020.3 1020.6 1020.9
Capital Lease Obligations 97.9 90 91.9 91.1 71
Deferred Income Tax 565.3 181 177.2 178.3 157.5
Minority Interest 34.1 33.5 34.1 64.9 76.6
Other Liabilities, Total 151.4 149.9 201.4 225.3 306
Total Equity 2594.6 2569.2 2420.3 2449.3 2272.8
Common Stock 18.4 18.4 18.4 18.4 18.4
Retained Earnings (Accumulated Deficit) 2576.2 2535.6 2401.8 2410.5 2254.3
Total Liabilities & Shareholders’ Equity 7958.9 5187.2 5096.7 5065.4 5097.1
Total Common Shares Outstanding 92.1673 92.1673 92.1673 92.1673 92.1802
Other Equity, Total 15.2 0.1 20.4 0.1
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 1130.4 646.7 482.63 317.419 284.549
Cash From Operating Activities 612.3 701.9 416.879 310.13 227.289
Cash From Operating Activities 181.7 141.6 102.282 73.368 60.914
Non-Cash Items -132.9 220.1 -9.77 14.859 -17.224
Cash Taxes Paid 221.2 166.6 113.98 65.328 65.537
Cash Interest Paid 10.3 8.3 8.064 10.528 8.995
Changes in Working Capital -566.9 -306.5 -158.263 -95.516 -100.95
Cash From Investing Activities -957.5 -465.2 -621.116 -184.373 -176.54
Capital Expenditures -430.6 -324 -159.192 -135.973 -176.54
Other Investing Cash Flow Items, Total -526.9 -141.2 -461.924 -48.4 0
Cash From Financing Activities 220.7 -77.7 234.066 -122.16 -59.594
Financing Cash Flow Items -52.4 -9.5 -34.059 -9.779 -7.209
Total Cash Dividends Paid -116.1 -62.7 -31.341 -52.543 -42.403
Issuance (Retirement) of Stock, Net -3.2
Issuance (Retirement) of Debt, Net 392.4 -5.5 299.466 -59.838 -9.982
Foreign Exchange Effects 8 4.8 1.767 0.593 0.268
Net Change in Cash -116.5 163.8 31.596 4.19 -8.577
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 148.6 1130.4 894.5 621 337.8
Cash From Operating Activities 165.6 612.3 392.7 247.3 171.7
Cash From Operating Activities 48.6 181.7 125.6 83.4 40.6
Non-Cash Items 5.6 -132.9 -120.7 -102.1 -75.8
Cash Taxes Paid 46.2 221.2 188.5 92.2 31.3
Cash Interest Paid 5.3 10.3 7.3 5.2 2.4
Changes in Working Capital -37.2 -566.9 -506.7 -355 -130.9
Cash From Investing Activities -115.8 -957.5 -809.5 -224.9 -122.3
Capital Expenditures -115.8 -430.6 -288.7 -179.9 -77.2
Other Investing Cash Flow Items, Total 0 -526.9 -520.8 -45 -45.1
Cash From Financing Activities -63.5 220.7 326.3 -97.7 -108.7
Financing Cash Flow Items -94 -52.4 -5 -4.1 -3.6
Total Cash Dividends Paid -132.7 -116.1 -116.1 -116.1 0
Issuance (Retirement) of Debt, Net 163.8 392.4 451 29.2 -99.5
Foreign Exchange Effects 0.7 8 12.3 7.8 0.7
Net Change in Cash -13 -116.5 -78.2 -67.5 -58.6
Issuance (Retirement) of Stock, Net -0.6 -3.2 -3.6 -6.7 -5.6
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Sartorius AG Corporation 73.5994 67844071 -200442 2022-12-31 LOW
Comgest S.A. Investment Advisor 0.9926 914961 217581 2023-09-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 0.7613 701779 3693 2023-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.7608 701340 -2413 2023-09-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 0.7377 680002 0 2023-09-30 LOW
Baillie Gifford & Co. Investment Advisor 0.7093 653833 0 2023-09-30 LOW
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 0.7053 650164 -1745 2023-09-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.6849 631363 119266 2022-12-31 LOW
Mawer Investment Management Ltd. Investment Advisor 0.4694 432739 50 2023-09-30 LOW
Invesco Advisers, Inc. Investment Advisor 0.431 397298 -198 2023-08-31 LOW
DNCA Investments Investment Advisor 0.3684 339578 -27698 2023-09-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 0.3083 284213 -90 2023-09-30 LOW
Capital Research Global Investors Investment Advisor 0.281 258983 23839 2023-09-30 LOW
BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund 0.2058 189730 1366 2023-09-30 LOW
Jupiter Asset Management Ltd. Investment Advisor/Hedge Fund 0.2031 187262 29336 2023-06-30 LOW
Credit Mutuel Asset Management Investment Advisor 0.1891 174269 -1500 2023-08-31 MED
Fidelity International Investment Advisor 0.1778 163878 60 2023-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.1706 157225 20 2023-09-30 LOW
Montanaro Asset Management Limited Investment Advisor 0.1635 150700 0 2023-09-30 LOW
AllianceBernstein L.P. Investment Advisor/Hedge Fund 0.1442 132950 -5062 2023-09-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Sartorius Stedim Biotech Company profile

About Sartorius Stedim Biotech SA

Sartorius Stedim Biotech SA is a France-based international provider of laboratory and process technologies and equipment. The Company covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The Company operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Sartorius Stedim Biotech SA revenues increased 51% to EUR2.89B. Net income applicable to common stockholders increased 23% to EUR414.4M. Revenues reflect EMEA segment increase of 60% to EUR829.1M, United States segment increase of 41% to EUR895.3M. Net income was partially offset by Financial Expense - Balancing value decrease from EUR1K (income) to EUR212.3M (expense).

Equity composition

07/2007, Company name changed from Stedim S.A. 05/2016, Scrip Issue, (Factor:5.99988).

Industry: Medical Equipment, Supplies & Distribution (NEC)

Zone Industrielle les Paluds Avenue de Jouques
Bp 1051
13781

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

XRP/USD

0.63 Price
-6.600% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Gold

1,996.96 Price
-0.400% 1D Chg, %
Long position overnight fee -0.0199%
Short position overnight fee 0.0117%
Overnight fee time 22:00 (UTC)
Spread 0.50

BTC/USD

42,218.15 Price
-4.110% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

US100

16,039.80 Price
-0.230% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading